Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have significantly improved the treatment of hormone receptor (HR)-positive breast cancer, while immune checkpoint inhibitors have reshaped therapeutic approaches for triple-negative breast cancer. The gene discussed is NR4A1; the disease is breast cancer.